Optimind Pharma Corp. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.060544 million compared to USD 0.014981 million a year ago. Basic loss per share from continuing operations was USD 0.01. Diluted loss per share from continuing operations was USD 0.01.
For the six months, net loss was USD 0.073407 million compared to USD 0.068953 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.